|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 490.00 TWD | -9.76% |
|
-12.19% | +0.41% |
| 02-03 | Bora Pharmaceuticals Unit to Buy CDMO Operational Assets for $18 Million | MT |
| 01-22 | Bora Pharmaceuticals Unit Gets US FDA Nod for Dry Eye Syndrome Drug | MT |
| Capitalization | 60.77B 1.94B 1.63B 1.49B 1.42B 2.64B 175B 2.74B 17.3B 6.87B 84.66B 7.26B 7.11B 296B | P/E ratio 2025 * |
14.1x | P/E ratio 2026 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise value | 72.63B 2.31B 1.95B 1.78B 1.7B 3.15B 210B 3.27B 20.68B 8.21B 101B 8.68B 8.5B 354B | EV / Sales 2025 * |
3.49x | EV / Sales 2026 * | 2.74x |
| Free-Float |
54.52% | Yield 2025 * |
1.64% | Yield 2026 * | 1.95% |
Last Transcript: Bora Pharmaceuticals Co., LTD.
| 1 day | -9.76% | ||
| 1 week | -12.19% | ||
| Current month | -18.74% | ||
| 1 month | -4.48% | ||
| 3 months | -13.73% | ||
| 6 months | -38.13% | ||
| Current year | +0.41% |
| 1 week | 489 |  | 568 |
| 1 month | 489 | | 633 |
| Current year | 476 | | 633 |
| 1 year | 468.41 | | 795 |
| 3 years | 292.28 | | 812.64 |
| 5 years | 83.5 | | 812.64 |
| 10 years | 8.6 | | 812.64 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pao Hsi Sheng
CEO | Chief Executive Officer | - | 20/10/2009 |
Chin Chu Wang
DFI | Director of Finance/CFO | - | 30/04/2013 |
Raymond Lee
CTO | Chief Tech/Sci/R&D Officer | - | 24/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Pao Hsi Sheng
CHM | Chairman | - | 25/08/2014 |
Shang Hung Shen
BRD | Director/Board Member | 67 | 25/08/2014 |
Shih Min Chen
BRD | Director/Board Member | - | 25/08/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.76% | -12.19% | -35.04% | +60.09% | 1.94B | |
| +0.33% | -1.72% | +23.18% | +199.23% | 929B | |
| -0.45% | +1.44% | +55.91% | +50.24% | 587B | |
| +1.76% | +3.61% | +20.03% | +51.71% | 409B | |
| +0.08% | +1.01% | +20.89% | +28.94% | 374B | |
| +1.42% | +7.19% | +26.36% | +32.36% | 320B | |
| +1.08% | +4.32% | +27.98% | +55.61% | 311B | |
| +1.82% | -0.43% | +46.26% | +11.65% | 301B | |
| +1.32% | +5.11% | -45.12% | -37.51% | 219B | |
| +1.52% | -3.94% | +26.80% | +53.17% | 199B | |
| Average | -0.09% | +0.35% | +16.72% | +50.55% | 365.07B | |
| Weighted average by Cap. | +0.74% | +1.57% | +26.51% | +76.74% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 20.84B 664M 559M 510M 487M 904M 60.1B 939M 5.93B 2.35B 29.02B 2.49B 2.44B 101B | 26.9B 857M 722M 659M 629M 1.17B 77.61B 1.21B 7.66B 3.04B 37.48B 3.21B 3.15B 131B |
| Net income | 4.19B 133M 112M 103M 97.92M 182M 12.09B 189M 1.19B 474M 5.84B 500M 490M 20.4B | 5.09B 162M 137M 125M 119M 221M 14.69B 230M 1.45B 576M 7.1B 608M 596M 24.8B |
| Net Debt | 11.86B 378M 318M 290M 277M 515M 34.22B 535M 3.38B 1.34B 16.53B 1.42B 1.39B 57.76B | 13.04B 415M 350M 319M 305M 565M 37.6B 588M 3.71B 1.47B 18.16B 1.56B 1.53B 63.47B |
Employees
-
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/02/26 | 490.00 NT$ | -9.76% | 4,107,775 |
| 10/02/26 | 543.00 NT$ | -2.69% | 1,129,333 |
| 09/02/26 | 558.00 NT$ | 0.00% | 837,880 |
| 06/02/26 | 558.00 NT$ | -2.62% | 965,439 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
490.00TWD
Average target price
741.02TWD
Spread / Average Target
+51.23%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 6472 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition